Imatinib in the Treatment of Nephrogenic Systemic Fibrosis

被引：36

作者：

Chandran, Sindhu ^{[1
]}

Petersen, Jeffrey ^{[1
]}

Jacobs, Charlotte ^{[2
]}

Forentino, David ^{[3
]}

Doeden, Katherine ^{[4
]}

Lafayette, Richard A. ^{[1
]}

机构：

[1] Stanford Univ, Div Nephrol, Stanford, CA 94305 USA

[2] Stanford Univ, Div Oncol, Stanford, CA 94305 USA

[3] Stanford Univ, Div Dermatol, Stanford, CA 94305 USA

[4] Stanford Univ, Div Pathol, Stanford, CA 94305 USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2009年 / 53卷 / 01期

关键词：

Imatinib; systemic fibrosis; dialysis; gadolinium; TYROSINE KINASE; TGF-BETA; DERMOPATHY; GADOLINIUM; FIBROGENESIS; INHIBITOR; LEUKEMIA; EFFICACY; SAFETY;

D O I：

10.1053/j.ajkd.2008.08.029

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

100201 [内科学]; 100221 [泌尿外科学];

摘要：

Nephrogenic systemic fibrosis is a disabling progressive condition that is being reported with increased frequency in patients with kidney disease. Treatment is extremely limited and largely supportive. We report a case of severe nephrogenic systemic fibrosis in a dialysis patient exposed to multiple doses of gadolinium who improved clinically and histologically with treatment with imatinib. Am J Kidney Dis 53:129-132. (C) 2008 by the National Kidney Foundation, Inc.

引用

收藏

页码：129 / 132

页数：4

相关论文

共 19 条

[1]

Baroni SS, 2006, NEW ENGL J MED, V354, P2667

[2]

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis [J].

Beham-Schmid, C ;

Apfelbeck, U ;

Sill, H ;

Tsybrovsky, O ;

Höfler, G ;

Haas, OA ;

Linkesch, W .

BLOOD, 2002, 99 (01) :381-383

[3]

Gadolinium deposition in nephrogenic fibrosing dermopathy [J].

Boyd, Alan S. ;

Zic, John A. ;

Abraham, Jerrold L. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) :27-30

[4]

Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned [J].

Broome, Dale R. ;

Girguis, Mark S. ;

Baron, Pedro W. ;

Cottrell, Alfred C. ;

Kjellin, Ingrid ;

Kirk, Gerald A. .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (02) :586-592

[5]

Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis [J].

Daniels, CE ;

Wilkes, MC ;

Edens, M ;

Kottom, TJ ;

Murphy, SJ ;

Limper, AH ;

Leof, EB .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (09) :1308-1316

[6]

Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review [J].

Daram, SR ;

Cortese, CM ;

Bastani, B .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (04) :754-759

[7]

Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure [J].

Deo, Aneet ;

Fogel, Mitchell ;

Cowper, Shawn E. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (02) :264-267

[8]

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis [J].

Distler, Joerg H. W. ;

Juengel, Astrid ;

Huber, Lars C. ;

Schulze-Horsel, Ursula ;

Zwerina, Jochen ;

Gay, Renate E. ;

Michel, Beat A. ;

Hauser, Thomas ;

Schett, Georg ;

Gay, Steffen ;

Distler, Oliver .

ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :311-322

[9]

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[10]

Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) [J].

Galan, Anjela ;

Cowper, Shawn E. ;

Bucala, Richard .

CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (06) :614-617